antisense technology, page-36

For those who say that Isis has nothing to do with Anp....wake up and smell the roses....



EP Vantage, a leading on line pharmaceutical comment and analysis service said “The approval in
the U.S. of Isis Pharmaceutical’s KynamroTM has finally validated antisense technology as a therapeutic approach. And for Isis’s long term collaborator, Antisense Therapeutics, the approval is more than
just affirmation of the technologies potential; it provides concrete advantages in the shape of clinical development pathway and a precedent that could help it hook partners and investors.”